Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity
Distributed through LillyDirect®'s self-pay channel, Zepbound single-dose vials are at least 50% less than the list price of all other incretin medicines for obesity INDIANAPOLIS , Aug. 27, 2024 /P...
Eli Lilly's Path to the Next Trillion Market Capitalization
Eli Lilly and Co. NYSE: LLY is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, known as Mounjaro for type 2 diabetes, and Zepbound for obesity. Its stoc...
Mounjaro Scores Yet Another Win: Why Eli Lilly Is Still a Buy
Eli Lilly's crown jewel performed well in another pivotal clinical trial. The medicine's potential looks even more attractive than it already did.
Prediction: These Will Be the Best-Performing S&P 500 Stocks of 2024
2024's best-performing S&P 500 stock so far should keep its top spot with a blow-out quarterly update this month. The No. 2 S&P 500 stock should continue to enjoy a massive tailwind throughout the ...
Eli Lilly's Growth Rate Is Fantastic, but This Number Is Even Better
Eli Lilly's sales rose by 36% last quarter to $11.3 billion. The company's low cost of sales has boosted its bottom line at a much higher rate.
Lilly (LLY) Up 3% on Obesity Drug Cutting Diabetes Risk
Eli Lilly (LLY) reports data from a late-stage study that found that long-term treatment with Zepbound reduces the risk of progression to type 2 diabetes by 94%.
Eli Lilly Stock Could Soar to $1,150, According to a Wall Street Analyst. Is It a Buy at Around $945?
Bank of America's price target for Eli Lilly implies a gain of about 25% from the stock's recent closing price. Eli Lilly's blockbuster weight management drug is gaining market share at a rapid pace.
Eli Lilly's Zepbound reduces type 2 diabetes risk, study shows
Eli Lilly announced results of a study in which weekly shots of tirzepatide injections significantly reduced the risk of progression to type 2 diabetes by 94% among certain adults.
Eli Lilly's Zepbound may be best-in-breed for weight loss drugs, says Dr. Kavita Patel
Dr. Kavita Patel joins 'Fast Money' to talk Eli Lilly's GLP-1 entrant cutting diabetes risk, the weight-loss drugs sector as a whole, and more.
Why Eli Lilly Stock Jumped to a Record High on Tuesday
Eli Lilly (LLY) stock jumped to a record high on Tuesday after clinical trial results showed tirzepatide—the active ingredient in Lilly's injectable weight-loss drug Zepbound and diabetes treatment...
Eli Lilly's weight loss drug slashes the risk of developing diabetes in long-term trial
Eli Lilly's weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with pre-diabetes compared to a placebo, according to initial results from a long-te...
Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight
176-week SURMOUNT-1 Phase 3 study in adults with pre-diabetes is the longest completed trial of tirzepatide to date Tirzepatide resulted in sustained weight loss through the treatment period, avera...
Prediction: These 2 Unstoppable Pharma Stocks Will Continue to Soar Through 2025 and Beyond
Novo Nordisk and Eli Lilly won't be constrained by manufacturing too much longer. That means they'll sell more of their in-demand drugs.
Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived
Last November, Eli Lilly received FDA approval for obesity drug Zepbound. In the second quarter, Zepbound generated over $1.2 billion in revenue!
Prediction: This Hypergrowth Company Could Be the Next Trillion-Dollar Stock
Eli Lilly is one of a few corporations close to hitting the $1 trillion mark. Despite a rich-looking valuation, the company should continue delivering strong returns.
Related Companies